Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 16/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | DLK1 | P80370 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21037498 | 0.84 | MAP3K12 (0.55) | MAP3K12ADRB1MAPK1 | |
| SCHEMBL13018943 | 0.83 | MAP3K12 (0.43) | MAP3K12NOS3NOS2ADRB1MAPK1 | |
| SCHEMBL2338512 | 0.81 | NOS3 (0.50) | MAP3K12NOS3NOS2ADRB1MAPK1 | |
| SCHEMBL28284245 | 0.78 | NOS3 (0.47) | MAP3K12NOS3NOS2ADRB1MAPK1 | |
| SCHEMBL3782541 | 0.77 | CHRNB2 (0.51) | MAP3K12NOS3NOS2ADRB1MAPK1 | |
| SCHEMBL28282678 | 0.77 | NOS3 (0.46) | MAP3K12NOS3NOS2ADRB1MAPK1 | |
| SCHEMBL31061341 | 0.77 | CHRNB2 (0.51) | MAP3K12NOS3NOS2ADRB1MAPK1 | |
| SCHEMBL24823772 | 0.76 | CCR1 (0.52) | NOS3NOS2 | |
| SCHEMBL3788239 | 0.76 | MAP3K12 (0.47) | MAP3K12TACR1 | |
| SCHEMBL29992344 | 0.75 | NOS3 (0.44) | MAP3K12NOS3NOS2ADRB1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331298-A1 | Carboxamide Compounds and Their Use | CYTOPATHFINDER, INC. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100210633-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE | EPIX DELAWARE, INC. (US) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331298-A1 | Carboxamide Compounds and Their Use | CCR2, CCR1, CCR5 | MAP3K12 1329/4885NOS3 2118/4885NOS2 1351/4885 |
| US-20100210633-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE | CCR2, CCR1, CCR5 | MAP3K12 1329/4885NOS3 2118/4885NOS2 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.